CASI Pharma (CASI) Tops Q1 EPS by 3c

CASI Pharma (NASDAQ: CASI) reported Q1 EPS of ($0.06), $0.03 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $9 million versus the consensus estimate of $9.23 million.

For earnings history and earnings-related data on CASI Pharma (CASI) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight